Prostate Cancer - Results from #2120

Circulating trans fatty acids are associated with prostate cancer in Ghanaian and American men. September 25, 2023

Exploring the Association Between Online Health Information and Racial Disparities in Prostate Cancer. September 25, 2023

A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma. September 25, 2023

Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. September 25, 2023

Alterations in the Epigenetic Machinery Associated with Prostate Cancer Health Disparities. September 25, 2023

LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. September 25, 2023

Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. September 25, 2023

Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. September 25, 2023

Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer. September 25, 2023

Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. September 25, 2023

A polygenic two-hit hypothesis for prostate cancer. September 25, 2023

A Transgender Patient with Prostate Cancer: Lessons Learnt. September 25, 2023

Aggressive Prostate Cancer Is Preventable and so Are Racial Disparities. September 25, 2023

Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. September 25, 2023

Racism Might Cause Prostate Cancer and Definitely Causes Excess Unemployment, Lost Wages, and Excess Cancer Deaths. September 25, 2023

Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer. September 25, 2023

Macrophages promote anti-androgen resistance in prostate cancer bone disease. September 25, 2023

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer. September 25, 2023

Barriers to and facilitators of prostate cancer screening among men in Uganda prisons. September 25, 2023

Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer. September 22, 2023

Page 107 of 1439